50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to transform cancer treatment by delivering innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining our deep understanding of tumor biology and translational medicine with our expertise in radiochemistry.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3086% match
“Our mission is to transform cancer therapy by reducing normal tissue toxicity induced by radiotherapy and increasing the anti-cancer efficacy of radiotherapy with the use of our dismutase mimetics.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-0875% match
“Our mission is to become a global leader in developing better and safer radioimmunotherapy and antibody-based oncology therapies addressing clear unmet medical needs and, as such, have a transformational impact on the lives of patients.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-0474% match
“Our mission is to accelerate the discovery, development and global access to targeted radioligand therapies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2770% match
“Our mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-02-2170% match
“Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-1569% match
“Our mission is to target cancer and transform lives through the development of innovative cancer treatments.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-1669% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2868% match
“Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest unmet medical need – aggressive cancers where current therapies are inadequate.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-02-2968% match
“Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2468% match
“Our mission is to transform cancer treatment and prevention globally by driving technological innovation and accelerating the adoption of precision oncology medicine.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-06-2268% match
“Our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3067% match
“Our mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through our subsidiary MiNK Therapeutics, Inc. (“MiNK”)), and vaccine adjuvants (through our subsidiary SaponiQx, Inc. (“SaponiQx”)).”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1467% match
“Our mission is to accelerate scientific and medical breakthroughs and deliver well-tolerated medicines with greater efficacy and safety to people with the deadliest cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0567% match
“Our mission is to develop and commercialize innovative antibody-based therapeutics for the treatment of solid tumors that are designed to bind depending on the physical and chemical properties of tumors and their microenvironment.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-04-2967% match
“Our mission is to become a leader in bringing innovative cancer treatments to the market and to improve patient health outcomes.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2067% match
“Our mission is to make a meaningful impact on the lives of patients with cancer and high unmet medical needs by delivering novel, PRAME-directed immunotherapies that provide tangible clinical benefits.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-0566% match
“Our mission is to use our proprietary Alpha DaRT technology to transform the treatment of solid tumors and broaden the potential scope of local radiotherapy delivery across multiple clinical settings.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-0966% match
“Our mission is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment of cancer.”In use 2025 – now·1 sighting·SEC Form S-1, filed 2025-07-1866% match
“Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1766% match
“Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0766% match
“Our mission is to discover, develop and ultimately deliver medicines that are transformational for patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2866% match
“Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0966% match
“Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1066% match
“Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0766% match
“Our mission is to improve overall patient condition through innovative bio-immunotherapy with proven treatment protocols, to lower deaths associated with cancer and to reduce the cost of cancer treatment.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-2566% match
“Our mission is to improve patient outcomes in the areas of neurodegenerative and oncological diseases by developing safe and effective cellular therapies that leverage the power of a patient’s immune system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-10-0866% match
“Our mission is to develop and commercialize safe and effective therapies that extend survival and maintain the quality of life for patients with life-threatening cancers and chronic liver diseases.”In use 2004 – now·1 sighting·SEC Form 10-K, filed 2004-12-1365% match
“Our mission is to improve human health and quality of life by transforming the way therapeutics and materials are discovered.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2565% match
“Our mission is to become a leading global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-01-2465% match
“Our mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0665% match
“Our mission is to develop new and effective immune-oncologic therapeutics.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-10-1465% match
“Our mission is to facilitate the stabilization, security and growth of the cardiac PET industry by providing cardiologists with: an economical, high-quality, PET imaging system; a reliable supply of radiopharmaceuticals for imaging procedures, and a comprehensive clinical, technical, support and service program.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-03-3165% match
“Our mission is to develop the full spectrum of medical uses for our special competence in precision-focused RF/microwave systems, and to broadly apply the utilization of our technology to treat cancer and benign diseases and conditions.”In use 2007 – now·1 sighting·SEC Form 10-K, filed 2007-11-1465% match
“Our mission is to significantly improve patient outcomes and address areas of high unmet medical need with our nanotechnology-based therapies.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-12-1165% match
“Our mission is to improve the lives of patients throughout the world by successfully identifying, developing and commercializing innovative specialty biopharmaceutical products.”In use 2014 – now·1 sighting·SEC Form 10-K, filed 2014-02-2865% match
“Our mission is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2365% match
“Our mission is to improve the lives of patients by developing novel therapeutics to treat some of the most devastating types of cancer.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-06-0265% match
“Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-1665% match
“Our mission is to leverage our unique insights into finding and binding cryptic functional pockets on currently intractable human biology-validated protein targets to discover, develop and commercialize small molecule therapies that can transform the lives of patients suffering from devastating cancers and immune disorders.”In use 2021 – now·1 sighting·SEC Form S-1, filed 2021-06-2565% match
“Our mission is to develop novel treatments for dormant cancers: targeting cancer resistance, metastasis, and relapse.”In use 2022 – now·1 sighting·SEC Form S-1/A, filed 2022-12-0865% match
“Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2265% match
“Our mission is to improve the quality of life of people suffering from cancer and to increase shareholder value by commercializing our platform technologies through in-house development, joint ventures, strategic alliances and licensing arrangements.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-07-2965% match
“Our mission is to become the leader in the development of a new generation of DXL™ -modified monoclonal antibodies that have significantly improved therapeutic potency and novel properties over un-modified monoclonal antibodies.”In use 2007 – now·1 sighting·SEC Form 20-F, filed 2007-12-2664% match
“Our mission is to use our technology to create a new generation of RNAi therapeutics which can improve outcomes for patients.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-09-0864% match
“Our mission is to be the leading player in the development and commercialization of p53-targeted cancer therapies.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1564% match
“Our mission is to create disease-modifying neurogenetic medicines by identifying validated targets, advancing multiple therapeutic modalities, and delivering them to the right areas within the central nervous system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1164% match
“Our mission is to develop, register and commercialize safe and effective drugs, with novel mechanisms of action, to meet the major unmet medical needs of patients on a global basis.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-1564% match
“Our mission is to provide a comprehensive and personalized approach to the clinical management of cancer through improved diagnostic, prognostic and therapeutic interventions.”In use 2010 – now·1 sighting·SEC Form 10-K, filed 2010-05-1764% match
“Our mission is to discover and develop effective biologic treatments for people with life-threatening conditions and to evolve Inhibrx into a commercial-stage biopharmaceutical company with a differentiated and sustainable product portfolio by focusing on the following:.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2864% match
Showing 1–50 of 50